The Journal of dermatologic surgery and oncology
-
J Dermatol Surg Oncol · Nov 1993
Meta AnalysisPooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
The trials of bacille Calmette-Guerin (BCG) as adjuvant therapy in malignant melanoma conducted over the preceding 2 decades have presented conflicting claims of efficacy. ⋯ Pooled analysis of non-placebo controlled trials of intralesional BCG for stage III malignant melanoma supports a trend to enhanced survival in patients with cutaneous non-visceral metastases.